Trial · NCT00103610
Results by group38
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 38
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Participants Able to Achieve Target (≥ 5*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis | G-CSF Plus Plerixafor | Proportion achieving target in ≤4 days | 0.593 | proportion of participants | |
| Proportion of Participants Able to Achieve Target (≥ 5*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis | G-CSF Plus Placebo | Proportion achieving target in ≤4 days | 0.196 | proportion of participants | |
| Proportion of Participants Able to Achieve Target (≥ 5*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis | G-CSF Plus Plerixafor | Proportion not achieving target in ≤4 days | 0.407 | proportion of participants | |
| Proportion of Participants Able to Achieve Target (≥ 5*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis | G-CSF Plus Placebo | Proportion not achieving target in ≤4 days | 0.804 | proportion of participants | |
| Number of Participants With Adverse Events | G-CSF Plus Plerixafor | Adverse Events (AEs) | 146 | participants | |
| Number of Participants With Adverse Events | G-CSF Plus Placebo | Adverse Events (AEs) | 138 | participants | |
| Number of Participants With Adverse Events | G-CSF Plus Plerixafor | Related AEs | 98 | participants | |
| Number of Participants With Adverse Events | G-CSF Plus Placebo | Related AEs | 60 | participants | |
| Number of Participants With Adverse Events | G-CSF Plus Plerixafor | AEs Leading to early treatment termination | 3 | participants | |
| Number of Participants With Adverse Events | G-CSF Plus Placebo | AEs Leading to early treatment termination | 3 | participants | |
| Number of Participants With Adverse Events | G-CSF Plus Plerixafor | AEs Leading to early study termination | 2 | participants | |
| Number of Participants With Adverse Events | G-CSF Plus Placebo | AEs Leading to early study termination | 4 | participants | |
| Number of Participants With Adverse Events | G-CSF Plus Plerixafor | Grade 3 (severe) or 4 (life-threatening) AEs | 11 | participants | |
| Number of Participants With Adverse Events | G-CSF Plus Placebo | Grade 3 (severe) or 4 (life-threatening) AEs | 14 | participants | |
| Number of Participants With Adverse Events | G-CSF Plus Plerixafor | SAEs | 8 | participants | |
| Number of Participants With Adverse Events | G-CSF Plus Placebo | SAEs | 10 | participants | |
| Proportion of Participants Able to Achieve Target (>=2*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis | G-CSF Plus Plerixafor | Proportion achieving target in ≤4 days | 0.867 | proportion of participants | |
| Proportion of Participants Able to Achieve Target (>=2*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis | G-CSF Plus Placebo | Proportion achieving target in ≤4 days | 0.473 | proportion of participants | |
| Proportion of Participants Able to Achieve Target (>=2*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis | G-CSF Plus Plerixafor | Proportion not achieving target in ≤4 days | 0.133 | proportion of participants | |
| Proportion of Participants Able to Achieve Target (>=2*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis | G-CSF Plus Placebo | Proportion not achieving target in ≤4 days | 0.527 | proportion of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00103610/results